The UK government recently published the Independent Review into Mental Health Conditions, ADHD and Autism, chaired by Professor Peter Fonagy. The final report runs to almost 600 pages and directly addresses the unprecedented rise in people seeking neurodevelopmental assessment and support. It accurately describes a system under immense strain, but some of its conclusions and the debate around them risk underestimating an important lifeline for patients: high-quality independent provision and the NHS Right to Choose pathway.
As a clinician working in ADHD care, I believe it is important to add balance to that discussion. Private clinics and Right to Choose are not a complete answer to the pressures facing the NHS, but when they are clinically robust, properly commissioned and well governed, they can expand capacity and help patients avoid years in clinical limbo.
Key findings: validating the distress
Real distress, real demand
The review rejects simplistic explanations for the rise in mental distress. It finds credible evidence that psychological distress has increased substantially among children and young people, shaped by a combination of social, economic and cultural factors. At the same time, the review distinguishes this from the underlying population prevalence of ADHD and autism, which appears to have remained much more stable.
The wait-list crisis
The scale of pressure is striking. NHS England monitoring data cited by the review shows the number of children and young people waiting for an ADHD assessment rising from around 21,000 in April 2019 to around 270,000 by December 2025. The underlying traits in the population have not changed at anything like the same speed, yet the number of people entering and waiting within assessment pathways has.
Diagnosis as a gateway
The final report is careful on this point: diagnosis has increasingly been perceived as a requirement for access to help. In practice, families and adults can still encounter systems in which a formal diagnosis makes it easier to secure recognition, treatment, adjustments or other forms of support. That can create strong incentives to pursue diagnostic assessment even when a person's immediate need is broader than diagnosis alone.
The debate about labels
The review raises legitimate concerns about excessive medicalisation and about allowing a diagnostic label to become the whole explanation for a person's identity, distress or prospects. Those are important safeguards. But for many people with ADHD, a diagnosis is not simply a label. It can provide a clinically useful framework for understanding years of difficulty, masking, shame or repeated underperformance, and it can open the door to evidence-based treatment when that is appropriate.
A clinician's analysis: the role of private care and Right to Choose
The Fonagy Review is right to challenge a system in which diagnosis can become the only route to basic support. Needs-led help should be available earlier wherever possible. But that should not be interpreted as an argument for making high-quality diagnostic assessment harder to access.
Public discussion sometimes treats independent ADHD provision as though it were a single, poorly governed sector. That is too crude. Quality varies across all healthcare settings, which is precisely why standards, accountability, commissioning and regulation matter. High-quality independent providers can add specialist capacity and, through Right to Choose, deliver NHS-funded care to patients who might otherwise face very long waits.
This is a simplified overview, not legal advice. Eligibility, clinical appropriateness and provider criteria apply.
Bypassing the postcode lottery
In England, legal patient-choice rights can apply to clinically appropriate elective mental-health referrals. For ADHD, that may include remote services and independent providers where the relevant NHS contracting requirements are met. Importantly, CQC registration on its own is not what makes a provider eligible for Right to Choose. The provider must be able to accept the relevant NHS referral under the applicable contractual framework.
Timelier intervention
Long waits are not neutral. Months or years without clarity or appropriate support can coincide with difficulty in education, work, relationships and mental health. Faster assessment does not guarantee a particular diagnosis or outcome, but reducing unnecessary delay can allow people to understand their needs sooner and, where indicated, move towards appropriate treatment or support.
Specialist, comprehensive care
Independent providers can build focused teams around neurodevelopmental care and may be able to offer assessment, medication titration, follow-up and psychoeducation within one pathway. However, provision is not identical across providers. Patients and referrers should check what is actually included, who is clinically responsible, how follow-up works and what happens if medication is recommended.
What the proposed changes could mean for ADHD care
The review made significant recommendations on regulation, commissioning and funding. The government's initial response on 9 October 2026 accepted the direction of travel in several areas, but not every recommendation is already law or in force. That distinction matters.
1. Wider CQC regulation of diagnostic assessment
The review recommends making diagnostic assessments for ADHD and autism a CQC-regulated activity. The government has said it will work towards bringing all such diagnostic assessments under CQC regulation, covering NHS-funded, non-NHS-funded and self-funded care. There is not yet a stated implementation date for universal regulation. Clinically, the principle is welcome: patients should be able to expect robust standards regardless of who funds their assessment.
2. Advertising is under review
The review recommends banning direct-to-public advertising of NHS-funded ADHD and autism assessments. The government's initial response stops short of announcing that ban as implemented policy; instead, the Secretary of State has said she will write to the Advertising Standards Authority about advertising practices. Clinics should expect greater scrutiny and should make sure public information is accurate, balanced and does not encourage unnecessary assessment.
3. A national NHS payment approach from April 2027
NHS England intends to consult on national prices for NHS-funded ADHD and autism services, including assessment, post-diagnostic support and follow-up, with finalised new payment arrangements intended from April 2027. If designed well, a more consistent payment framework could improve transparency for providers and commissioners and reduce some of the variation that currently complicates Right to Choose pathways.
4. The opportunity and risk of needs-led support
The review recommends moving away from systems in which a diagnosis is the main gateway to help. In principle, that is positive: children and adults should not have to wait years for basic adjustments or early support. The risk is implementation. Needs-led support only works if schools, employers, primary care and community services have the capacity, skills and funding to deliver it. Otherwise, removing diagnosis as a formal gateway could become a mechanism for delaying specialist care rather than widening support.
The bottom line
The Fonagy Review is an important acknowledgement that the current system is under unsustainable pressure. It is also right to demand consistent standards, better oversight and earlier support that is not dependent on a diagnostic label.
But the route forward should not involve treating independent healthcare or Right to Choose as the problem. Well-regulated private and independent providers can be valuable NHS partners, adding capacity while patients continue to exercise legitimate rights to choice. The objective should be straightforward: protect timely access, raise quality, make commissioning more transparent and ensure that every assessment is clinically robust.
For people seeking help with ADHD, the debate should ultimately be judged by whether it produces safer care, shorter waits, clearer support and better outcomes.
This is clinical commentary by Husain Vali and reflects his interpretation of the published evidence and policy position as at 30 October 2026. It is not legal advice, individual medical advice or a statement that My Neuro Health currently provides NHS Right to Choose services.
Evidence and policy referenced
- Department of Health and Social Care — Independent review into mental health conditions, ADHD and autism: final report (published 9 October 2026; updated 21 October 2026).
- Fonagy Review — executive summary.
- Department of Health and Social Care — government response to the review (9 October 2026).
- NHS England — Patient choice guidance.
- NHS — ADHD in adults, including information on assessment and Right to Choose.